Statistics for INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)
Total visits
| views | |
|---|---|
| INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG) | 4 |
Total visits per month
| views | |
|---|---|
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 2 |
| May 2025 | 0 |
| June 2025 | 0 |
| July 2025 | 2 |
| August 2025 | 0 |
File Visits
| views | |
|---|---|
| hdl_138674.pdf | 5 |